Page 5 - Long-term surveillance following resection of pheochromocytoma

Kumar et al

many years after surgery and are seen more frequently in 9. Plouin PF, Gimenez-Roqueplo AP. Initial workup and long-term followup in patients with pheo -
chromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 2006a;20:421-34.
patients with a genetic disease, young age, large tumor, and https://doi.org/10.1016/j.beem.2006.07.004
extra-adrenal disease. All patients should be considered for 10. Hamidi O, Young WF Jr, Iniguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma:
genetic testing. Patients should be screened with plasma and 272 patients over 55 years. J Clin Endocrinol Metab 2017;102:3296-305. https://doi.org/10.1210/
urinary metanephrines postoperatively, and yearly thereafter jc.2017-00992
for at least 10 years, and potentially indefinitely for higher- 11. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and pheochromocytoma: From genetics to per-
sonalized medicine. Nat Rev Endocrinol 2015;11:101-11. https://doi.org/10.1038/nrendo.2014.188
risk patients. 12. Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem
A summary of all BPR recommendations is shown in 2014;60:1486-99. https://doi.org/10.1373/clinchem.2014.224832
Table 1. 13. Lenders JW, Keiser HR, Goldstein DS, et al. Plasma metanephrines in the diagnosis of pheochromocytoma.
Ann Intern Med 1995;123:101-9. https://doi.org/10.7326/0003-4819-123-2-199507150-00004
Competing interests: Dr. Violette has been a speakers’ bureau member for Janssen and Sanofi (no 14. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: Which test is
honoraria). Dr. Tomiak has received speaker honoraria from AstraZeneca. Dr. Izard has received best? JAMA 2002;287:1427-34. https://doi.org/10.1001/jama.287.11.1427
advisory board and consulting fees from Abbvie, Astellas, Ferring, Janssen, and Sanofi; and has 15. Perry CG, Sawka AM, Singh R, et al. The diagnostic efficacy of urinary fractionated metanephrines measured
by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 2007;66:703-8/
participated in clinical trials supported by Astellas, AstraZeneca and Merck. Dr. Rowe has participated https://doi.org/10.1111/j.1365-2265.2007.02805.x
in an advisory board meeting for Acerus and has received honoraria from Sanofi. The remaining 16. Amar L, Lussey-Lepoutre C, Lenders JW, et al. Recurrence or new tumors after complete resection of
authors report no competing personal or financial interests related to this work. pheochromocytomas and paragangliomas: A systematic review and meta-analysis. Eur J Endocrinol
2016;175:R135-45. https://doi.org/10.1530/EJE-16-0189
17. Plouin PF, Amar L, Dekkers OM, et al. European Society of Endocrinology clinical practice guideline for
Prior to publication, this BPR underwent review by the CUA Guidelines Committee, CUA members long-term followup of patients operated on for a pheochromocytoma or a paraganglioma. Eur J Endocrinol
at large, the CUAJ Editorial Board, and the CUA Executive Board. 2016;174:G1-0. https://doi.org/10.1530/EJE-16-0033
18. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: How
to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003b;88:2656-66.
https://doi.org/10.1210/jc.2002-030005
19. Algeciras-Schimnich A, Preissner CM, Young WF Jr, et al. Plasma chromogranin A or urine fractionated
References metanephrines followup testing improves the diagnostic accuracy of plasma fractionated metanephrines for
pheochromocytoma. J Clin Endocrinol Metab 2008;93:91-5. https://doi.org/10.1210/jc.2007-1354
1. Bravo EL, Tagle R. Pheochromocytoma: State-of-the-art and future prospects. Endocr Rev 2003;24:539-53. 20. Timmers HJ, Pacak K, Huynh TT, et al. . Biochemically silent abdominal paragangliomas in patients with
https://doi.org/10.1210/er.2002-0013 mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 2008;93:4826-32.
2. Nakamura E, Kaelin WG Jr. Recent insights into the molecular pathogenesis of pheochromocytoma and https://doi.org/10.1210/jc.2008-1093
paraganglioma. Endocr Pathol 2006;17:97-106. https://doi.org/10.1385/EP:17:2:97 21. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imaging workup for screening of paraganglioma
3. Benn DE, Robinson BG. Genetic basis of pheochromocytoma and paraganglioma. Best Pract Res Clin and pheochromocytoma in SDHx mutation carriers: A multicenter prospective study from the PGL.EVA
Endocrinol Metab 2006;20:435-50. https://doi.org/10.1016/j.beem.2006.07.005 Investigators. J Clin Endocrinol Metab 2013;98:E162-73. https://doi.org/10.1210/jc.2012-2975
4. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheo- 22. Timmers HJ, Chen CC, Carrasquillo JA, et al. Staging and functional characterization of pheochromocytoma
chromocytoma. J Clin Endocrinol Metab 2004;89:479-91. https://doi.org/10.1210/jc.2003-031091 and paraganglioma by 18F- fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer
5. Lenders JW, Eisenhofer G, Mannelli M, et al. Pheochromocytoma. Lancet 2005;366:665-75. Inst 2012;104:700-8. https://doi.org/10.1093/jnci/djs188
https://doi.org/10.1016/S0140-6736(05)67139-5 23. Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheo-
6. Scholz T, Eisenhofer G, Pacak K, et al. Current treatment of malignant pheochromocytoma. J Clin Endocrinol chromocytoma and paraganglioma. Eur J Endocrinol 2014;171:R111-22. https://doi.org/10.1530/
Metab 2007;92:1217-25. https://doi.org/10.1210/jc.2006-1544 EJE-14-0113
7. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: An endocrine society
clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42. https://doi.org/10.1210/ Correspondence: Dr. Neal Rowe, Division of Urology, Department of Surgery, The Ottawa Hospital,
jc.2014-1498 University of Ottawa, Ottawa, ON, Canada; nealrowe81@gmail.com
8. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk
of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab
2005b;90:2110-6. https://doi.org/10.1210/jc.2004-1398

376 CUAJ • December 2019 • Volume 13, Issue 12